Anyone on the forum heard of ND 0612 . This concerns the subcutaneous administration of levodopa/carbidopa via an intelligent pump system. Supposed to be undergoing clinical trials stage III at the moment.
this is not the same as duadopa administered directly into the duodenum which is far more invasive. Sounds as if it might be a solution for those who find variable results from oral intake of Parkinson’s drugs?